| 23.04 Data as of May 17 |  -0.13 / -0.56%Today’s Change | 15.43 Today|||52-Week Range 26.30 | +38.71% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.1B |
Incyte Corp. Experimental Station Wilmington Delaware 19880 |
| Mutual fund holders | 72.44% |
| Other institutional | 41.71% |
| Individual stakeholders | 15.57% |
| Paul A. Friedman, MD | President, Chief Executive Officer & Director |
| David C. Hastings, CPA | Chief Financial Officer & Executive Vice President |
| Richard S. Levy, MD | EVP, Chief Drug Development & Medical Officer |
| James M. Daly, MBA | Chief Commercial Officer & Executive VP |
| Eric H. Siegel, MBA | Secretary, Executive VP & General Counsel |
.
